ATE508739T1 - Carboxylsäuren un deren derivate und pharmazeutische zusammensetzungen die diese enthalten - Google Patents

Carboxylsäuren un deren derivate und pharmazeutische zusammensetzungen die diese enthalten

Info

Publication number
ATE508739T1
ATE508739T1 AT98925875T AT98925875T ATE508739T1 AT E508739 T1 ATE508739 T1 AT E508739T1 AT 98925875 T AT98925875 T AT 98925875T AT 98925875 T AT98925875 T AT 98925875T AT E508739 T1 ATE508739 T1 AT E508739T1
Authority
AT
Austria
Prior art keywords
substituted
chain
derivatives
pharmaceutical compositions
carboxylic acids
Prior art date
Application number
AT98925875T
Other languages
German (de)
English (en)
Inventor
Jacob Bar-Tana
Original Assignee
Syndrome X Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syndrome X Ltd filed Critical Syndrome X Ltd
Application granted granted Critical
Publication of ATE508739T1 publication Critical patent/ATE508739T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98925875T 1997-06-26 1998-06-23 Carboxylsäuren un deren derivate und pharmazeutische zusammensetzungen die diese enthalten ATE508739T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL12116597A IL121165A0 (en) 1997-06-26 1997-06-26 Pharmaceutical compositions containing carboxylic acids and derivatives thereof
PCT/IB1998/000968 WO1999000116A2 (en) 1997-06-26 1998-06-23 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
ATE508739T1 true ATE508739T1 (de) 2011-05-15

Family

ID=11070308

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98925875T ATE508739T1 (de) 1997-06-26 1998-06-23 Carboxylsäuren un deren derivate und pharmazeutische zusammensetzungen die diese enthalten

Country Status (10)

Country Link
US (1) US6303653B1 (enExample)
EP (1) EP1001755B1 (enExample)
JP (1) JP2002507209A (enExample)
CN (2) CN101129349A (enExample)
AT (1) ATE508739T1 (enExample)
AU (1) AU7783998A (enExample)
CA (1) CA2294232A1 (enExample)
IL (2) IL121165A0 (enExample)
RU (1) RU2239427C2 (enExample)
WO (1) WO1999000116A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020037876A1 (en) * 1998-06-25 2002-03-28 Yissum Research Development Company Of Hebrew University Of Jerusalem Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
CN1329359C (zh) 1999-04-01 2007-08-01 埃斯佩里安医疗公司 醚化合物,及其组合物和用途
WO2002009691A1 (en) * 2000-08-02 2002-02-07 Pharmanutrients Methods and compositions for the prevention and treatment of syndrome x
AU2001290241A1 (en) * 2000-09-20 2002-04-02 Kyowa Hakko Kogyo Co. Ltd. Tumor cell proliferation inhibitors
US7304093B2 (en) 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
MXPA03003021A (es) 2000-10-11 2003-07-14 Esperion Therapeutics Inc Compuestos de eter y composiciones para el control del colesterol y usos relacionados.
CN1283610C (zh) 2000-10-11 2006-11-08 埃斯佩里安医疗公司 用于控制胆固醇以及相关用途的酮化合物以及组合物
JP2004532799A (ja) 2000-10-11 2004-10-28 エスペリオン セラピューティクス，インコーポレイテッド コレステロール管理および関連用途のためのスルフィド化合物およびジスルフィド化合物ならびにそれらを含む組成物
JP2004531459A (ja) 2000-10-11 2004-10-14 エスペリオン セラピューティクス，インコーポレイテッド コレステロールマネージメント用スルホキシドおよびビススルホキシド化合物ならびに組成物および関連する使用
NO20006008L (no) * 2000-11-28 2002-05-29 Thia Medica As Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer
WO2003105860A1 (en) * 2002-06-14 2003-12-24 Novo Nordisk A/S Pharmaceutical use of boronic acids and esters thereof
JP4931349B2 (ja) 2003-01-23 2012-05-16 エスペリオン セラピューティクス，インコーポレイテッド コレステロール管理およびそれに関連した使用に供するヒドロキシル化合物および組成物
CA2549995C (en) 2003-12-24 2011-11-15 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
CA2550943A1 (en) * 2003-12-30 2005-07-14 Syndrome X Ltd. Methods of administering 3,3,14,14 tetramethyl hexadecane 1,16 dioic acid
KR20050118057A (ko) * 2004-04-24 2005-12-15 김상희 아세틸디아실글리세롤류의 화합물을 유효성분으로함유하는 항암제 및 건강식품
CN101365446B (zh) 2005-07-29 2013-05-22 雷斯弗洛吉克斯公司 预防和治疗复杂疾病的药物组合物及其经由可植入医药装置的递送
WO2007137864A1 (en) * 2006-06-01 2007-12-06 Eucro European Contract Research Gmbh & Co. Kg Use of inhibitors of pp2c for treating or preventing arteriosclerosis
WO2008018877A1 (en) 2006-08-11 2008-02-14 Ssv Therapeutics, Inc. Carnitine conjugates as dual prodrugs, methods of production and uses thereof
DK2118074T3 (en) 2007-02-01 2014-03-10 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular diseases
IL181577A0 (en) * 2007-02-26 2007-07-04 Jacob Bar Tana Combination therapy composition and methods for the treatment of cardiovascular disorders and immune-related disorders
US8481084B2 (en) 2007-05-23 2013-07-09 Amcol International Corporation Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
DE102007051339A1 (de) * 2007-10-26 2009-04-30 Müller-Enoch, Dieter, Prof. Dr. Verwendung von Verbindungen der Formel A-R-X oder deren pharmazeutisch akzeptablen Salze zur Herstellung einer pharmazeutischen Zubereitung zur Behandlung und zur Vorbeugung von Dyslipidämien
EP2085082A1 (en) * 2008-01-29 2009-08-05 Nutromnia S.R.L. Treatment of cognitive decline
ES2532402T3 (es) 2008-06-26 2015-03-26 Resverlogix Corporation Métodos de preparación de derivados de quinazolinona
JP5635535B2 (ja) 2009-01-08 2014-12-03 レスバーロジックス コーポレイション 心血管疾患の予防および治療のための化合物
WO2010083311A2 (en) * 2009-01-14 2010-07-22 Vanas Oncology Compositions and methods of use
CN105859639A (zh) 2009-03-18 2016-08-17 雷斯韦洛吉克斯公司 新的抗炎剂
EP2414042A4 (en) * 2009-03-31 2013-01-30 Matthew R Witten RADIATION THERAPY TREATMENT SYSTEM AND METHOD FOR PROVIDING USE OF A MIMETIC OPTIMIZATION ALGORITHM
CN107252429B (zh) 2009-04-22 2023-06-16 雷斯韦洛吉克斯公司 新抗炎剂
ES2670576T3 (es) 2009-09-03 2018-05-31 Pfizer Vaccines Llc Vacuna de PCSK9
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
JP5992049B2 (ja) 2011-11-01 2016-09-14 レスバーロジックス コーポレイション 置換されたキナゾリノンのための経口速放性製剤
US10479752B2 (en) * 2011-12-08 2019-11-19 Syndromex Ltd. Deuterated tetramethyl dioic acids, compositions comprising them and uses thereof
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
CN114984016A (zh) 2015-03-13 2022-09-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
MX392182B (es) 2015-03-13 2025-03-21 Esperion Therapeutics Inc Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
US20180092874A1 (en) * 2016-10-03 2018-04-05 Lincoln Memorial University Identification and use of very long chain dicarboxylic acids for disease diagnosis, chemoprevention, and treatment
JP7234151B2 (ja) * 2017-07-07 2023-03-07 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 脂肪酸誘導体およびこれらの使用
US12344578B2 (en) 2019-06-21 2025-07-01 Esperion Therapeutics, Inc. Salt forms of bempedoic acid and methods for using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL64542A0 (en) 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
DE3423166A1 (de) 1984-06-22 1986-01-02 Epis S.A., Zug Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
DE4224670A1 (de) 1992-07-25 1994-01-27 Boehringer Mannheim Gmbh Verwendung von â,w-Dicarbonsäuren als Fibrinogensenker
ATE183391T1 (de) * 1993-12-31 1999-09-15 Univ Limburg Verwendung von zusammensetzungen essentieller fettsäuren
IL119971A (en) 1997-01-07 2003-02-12 Yissum Res Dev Co Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
PL343902A1 (en) * 1997-02-21 2001-09-10 Abbott Lab Methods of and compositions for reducing enteritis and colitis morbidity rate

Also Published As

Publication number Publication date
JP2002507209A (ja) 2002-03-05
WO1999000116A3 (en) 1999-08-12
CA2294232A1 (en) 1999-01-07
WO1999000116A2 (en) 1999-01-07
AU7783998A (en) 1999-01-19
EP1001755B1 (en) 2011-05-11
IL121165A0 (en) 1997-11-20
IL133540A (en) 2009-09-22
EP1001755A2 (en) 2000-05-24
US6303653B1 (en) 2001-10-16
CN1261274A (zh) 2000-07-26
CN101129349A (zh) 2008-02-27
RU2239427C2 (ru) 2004-11-10

Similar Documents

Publication Publication Date Title
ATE508739T1 (de) Carboxylsäuren un deren derivate und pharmazeutische zusammensetzungen die diese enthalten
ES2122076T3 (es) Derivados de nor-acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos.
RU94039542A (ru) Производные пиперазина как антагонисты 5-нт-рецепторов, способ получения, фармацевтическая композиция
FI972621A0 (fi) Ei-steroidisten tulehduksenvastaisten karboksyylihappojen estereitä ja amideja, joita voidaan käyttää antioksidantteina, 5-lipoksigenaasi-inhibiittoreina ja ei-steroidisina tulehduksenvastaisina tuotteina
BR9401484A (pt) Hidrazida de ácido 1h-indol-3-acético e formulação farmacêutica
ATE149485T1 (de) Substituierte heterocyclische carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel
ATE386508T1 (de) Feste orale dosierungsform enthaltend einen resorptionsverstärker
KR880006993A (ko) 베타-아드레날린을 함유하는 동물사육 조성물
DE69420068D1 (de) 1H-Indol-3-Acetamid-Derivate als sPLA2-Inhibitoren
ATE153334T1 (de) 7-chromanylester von phenolen und benzoesäuren mit retinoidähnlicher aktivität
ES2100200T3 (es) Metalocenos con derivados biciclicos de ciclopentadieno como ligandos, procedimiento para su preparacion y su empleo como catalizadores.
ES2095529T3 (es) Derivados de los acidos carboxilicos como inhibidores de la 5-alfa-reductasa.
EE200000504A (et) Bensofurüül-a-pürooni derivaadid, farmatseutilinekompositsioon, lipiidide ainevahetuse kiirendaja,triglütseriidi biosünteesi inhibiitor, vere triglütseriiditaset alandav toimeaine, vere HDL taset tõstev toimeaine, arterioskleroosi profülaktiline to
AR050463A1 (es) Analagos de lonidamina y su uso en anticoncepcion masculina y en el tratamiento contra el cancer.
ATE152728T1 (de) Pyrazolopyrimidin- und pyrimidinylbisphosphonsäureester als entzündungshemmende mittel
GB1320181A (en) Cyclic carboxylic acid derivatives
ES2122303T3 (es) Nuevos agentes antivirales.
DE59200387D1 (de) Heterocyclisch substituierte Chinolylmethoxy-Phenylacetamide als Lipoxygenasehemmer.
ES2122221T3 (es) Compuestos terapeuticos adecuados para el tratamiento de enfermedades conectadas con la deficiencia de glutation, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ATE34662T1 (de) Derivate der benzoesaeure, herstellungsverfahren und anwendung in desinfizierenden und konservierenden arzneimitteln.
DE69324862D1 (de) Arzneimittel, die Ester omega-3 polyungesättigter Säuren enthalten und deren Verwendung in der topischen Behandlung morbider Erkrankungen
EA202190890A1 (ru) Получение замещенных ароматических соединений и их применение в фармацевтике
NZ214640A (en) Trienamide derivatives and pharmaceutical compositions having anti-inflammatory and analgesic activity
ES398802A1 (es) Procedimiento para la preparacion de acidos propionicos sustituidos por fenilo en la posicion 2.
DE69400352D1 (de) 3- oder 4-Glykosyloxybenzopyranderivat und dieses enthaltende antiallergisches Mittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties